Amylyx Pharmaceuticals(AMLX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AMLX Amylyx Pharmaceuticals

交易中 05-29 10:30:59 EDT

13.99

-0.23

-1.62%

最高14.36	最低13.99	成交量7.79万
今开14.19	昨收14.22	日振幅2.57%
总市值15.55亿	流通市值9.16亿	总股本1.11亿
成交额110.06万	换手率0.12%	流通股本6,545万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AMLX","market":"US","secType":"STK","nameCN":"Amylyx Pharmaceuticals","latestPrice":13.99,"timestamp":1780065051232,"preClose":14.22,"halted":0,"volume":77909,"delay":0,"changeRate":-0.016174402250351647,"floatShares":65449399,"shares":111186317,"eps":-1.48947,"marketStatus":"交易中","change":-0.23,"latestTime":"05-29 10:30:59 EDT","open":14.19,"high":14.355,"low":13.99,"amount":1100644.0494269999,"amplitude":0.025668,"askPrice":14,"askSize":34,"bidPrice":13.95,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.48947,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1780084800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1641531600000,"exchange":"NASDAQ","adjPreClose":14.22,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":14.21,"preClose":14.22,"latestTime":"08:43 EDT","volume":1082,"amount":15381.259724,"timestamp":1780058613974,"change":-0.01,"changeRate":-0.000703,"amplitude":0.017581},"postHourTrading":{"tag":"盘后","latestPrice":14.2,"preClose":14.22,"latestTime":"19:10 EDT","volume":11239,"amount":159809.1,"timestamp":1780009859337,"change":-0.02,"changeRate":-0.001406,"amplitude":0.004219},"volumeRatio":0.68041,"impliedVol":1.2415,"impliedVolPercentile":0.9641},"requestUrl":"/m/hq/s/AMLX","defaultTab":"news","newsList":[{"id":"1171717586","title":"Amylyx制药公司宣布AMX0035的2期开放标签Helios试验数据在《临床研究杂志》上经同行评审发表","url":"https://stock-news.laohu8.com/highlight/detail?id=1171717586","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171717586?lang=zh_cn&edition=full","pubTime":"2026-05-16 00:12","pubTimestamp":1778861536,"startTime":"0","endTime":"0","summary":"Amylyx制药公司宣布，其针对AMX0035的2期开放标签Helios试验数据，已在权威医学期刊《临床研究杂志》上经同行评审后正式发表。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144099678","title":"Amylyx制药公司宣布针对成人减重手术后低血糖的美国扩大可及计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1144099678","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144099678?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:07","pubTimestamp":1777979260,"startTime":"0","endTime":"0","summary":"Amylyx制药公司近日公布了一项针对成人减重手术后低血糖（PBH）患者的美国扩大可及计划（EAP）。该计划旨在为符合条件的PBH成年患者提供其在研药物的获取渠道。\n扩大可及计划通常允许尚未获得正式批准的治疗方案在特定条件下提供给有迫切医疗需求的患者。此举显示了Amylyx公司致力于解决这一罕见且严重代谢紊乱疾病的承诺。\n减重手术后低血糖是一种可能发生在减肥手术后的并发症，其特征是餐后血糖水平异常低下。该计划有望为受此病症困扰的患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153109103","title":"Amylyx制药公司Avexitide三期LUCIDITY试验顶线数据预计2026年第三季度揭晓","url":"https://stock-news.laohu8.com/highlight/detail?id=1153109103","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153109103?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:07","pubTimestamp":1777979235,"startTime":"0","endTime":"0","summary":"Amylyx制药公司宣布，其候选药物Avexitide的关键三期LUCIDITY临床试验的顶线数据结果，预计将于2026年第三季度公布。这项备受关注的试验数据读出，将为评估Avexitide的疗效和安全性提供关键依据。\n此次数据发布将成为衡量该疗法潜力的重要里程碑，对公司的未来发展方向具有决定性意义。投资者和医学界正密切关注这一进展，期待试验结果能为相关疾病治疗带来新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198448310","title":"Amylyx Pharmaceuticals宣布Avexitide用于减重手术后低血糖症的关键3期LUCIDITY临床试验完成患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1198448310","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198448310?lang=zh_cn&edition=full","pubTime":"2026-03-24 19:01","pubTimestamp":1774350093,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals宣布，其针对Avexitide治疗减重手术后低血糖症（PBH）的关键性3期LUCIDITY临床试验已完成患者入组。该研究的完成标志着药物开发进程中的一个重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619152165","title":"Amylyx Pharmaceuticals, Inc.盘中异动 大幅跳水5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619152165","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619152165?lang=zh_cn&edition=full","pubTime":"2026-03-12 21:31","pubTimestamp":1773322266,"startTime":"0","endTime":"0","summary":"北京时间2026年03月12日21时31分，Amylyx Pharmaceuticals, Inc.股票出现波动，股价快速下挫5.06%。Amylyx Pharmaceuticals, Inc.股票所在的制药行业中，整体跌幅为0.65%。其相关个股中，Im Cannabis Corp.、Alpha Teknova, Inc.、Cbdmd, Inc.涨幅较大，Incannex Healthcare Inc.、Hims & Hers Health, Inc.、Medicus Pharma Ltd.较为活跃，换手率分别为7.55%、2.77%、1.18%，振幅较大的相关个股有Alpha Teknova, Inc.、Indivior Pharmaceuticals, Inc.、Im Cannabis Corp.，振幅分别为4.24%、3.94%、3.64%。Amylyx Pharmaceuticals, Inc.公司简介：Amylyx Pharmaceuticals Inc 是一家处于临床阶段的制药公司，致力于开发治疗肌萎缩性侧索硬化症和其他神经退行性疾病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312213107a6bb0731&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312213107a6bb0731&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AMLX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617563634","title":"Amylyx Pharmaceuticals, Inc.盘中异动 股价大涨5.07%报14.83美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617563634","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617563634?lang=zh_cn&edition=full","pubTime":"2026-03-05 00:28","pubTimestamp":1772641728,"startTime":"0","endTime":"0","summary":"北京时间2026年03月05日00时28分，Amylyx Pharmaceuticals, Inc.股票出现异动，股价大幅拉升5.07%。Amylyx Pharmaceuticals, Inc.股票所在的制药行业中，整体跌幅为0.15%。Amylyx Pharmaceuticals, Inc.公司简介：Amylyx Pharmaceuticals Inc 是一家处于临床阶段的制药公司，致力于开发治疗肌萎缩性侧索硬化症和其他神经退行性疾病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305002849954304bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305002849954304bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AMLX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126567197","title":"Amylyx Pharmaceuticals现金储备预计足以支撑运营至潜在Avexitide商业化阶段并延续至2028年","url":"https://stock-news.laohu8.com/highlight/detail?id=1126567197","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126567197?lang=zh_cn&edition=full","pubTime":"2026-03-03 20:11","pubTimestamp":1772539870,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals公司宣布，其现有现金储备预计将足以支持公司运营，不仅能够覆盖潜在新药Avexitide的商业化进程，还可维持至2028年。这一资金规划为公司的中长期发展提供了稳定的财务基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148151135","title":"Amylyx制药公司——三期Lucidity试验关键数据预计2026年第三季度公布，2027年实现商业化上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1148151135","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148151135?lang=zh_cn&edition=full","pubTime":"2026-03-03 20:10","pubTimestamp":1772539825,"startTime":"0","endTime":"0","summary":"备受关注的Amylyx制药公司近日披露了其研发管线的重要进展。公司旗下备受期待的三期临床试验——Lucidity研究，其关键性顶层数据预计将于2026年第三季度揭晓。这一时间点的明确，为关注该药物前景的投资者和医学界提供了清晰的预期。\n基于这一积极的时间表，公司进一步规划，若试验结果达到预期目标，该药物的商业化上市进程预计将在2027年正式启动。这一系列规划，标志着Amylyx在相关治疗领域的探索进入了关键冲刺阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606719156","title":"Amylyx Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606719156","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606719156?lang=zh_cn&edition=full","pubTime":"2026-01-28 00:08","pubTimestamp":1769530089,"startTime":"0","endTime":"0","summary":"北京时间2026年01月28日00时08分，Amylyx Pharmaceuticals, Inc.股票出现波动，股价快速拉升5.20%。截至发稿，该股报15.79美元/股，成交量30.9861万股，换手率0.28%，振幅6.06%。机构评级方面，在所有10家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。Amylyx Pharmaceuticals, Inc.股票所在的制药行业中，整体涨幅为1.37%。Amylyx Pharmaceuticals, Inc.公司简介：Amylyx Pharmaceuticals Inc 是一家处于临床阶段的制药公司，致力于开发治疗肌萎缩性侧索硬化症和其他神经退行性疾病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012800081097a3a59c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012800081097a3a59c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AMLX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105804341","title":"Amylyx Pharmaceuticals提名AMX0318为新型长效GLP-1受体拮抗剂开发候选药物，该成果系与Gubra A/S合作发现","url":"https://stock-news.laohu8.com/highlight/detail?id=1105804341","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105804341?lang=zh_cn&edition=full","pubTime":"2026-01-08 20:12","pubTimestamp":1767874342,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals近日正式提名AMX0318作为其新型长效GLP-1受体拮抗剂开发候选药物。这一重要里程碑源于该公司与Gubra A/S的协同研究合作。AMX0318的独特机制有望为代谢性疾病治疗开辟新路径，其长效特性可能显著改善患者用药依从性。此次候选药物提名标志着合作项目正式进入下一阶段开发流程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177552511","title":"Amylyx Pharmaceuticals发布首例人体试验Lumina试验中Amx0114在ALS中安全性和耐受性Cohort 1的新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1177552511","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177552511?lang=zh_cn&edition=full","pubTime":"2025-12-05 22:02","pubTimestamp":1764943357,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals发布首例人体试验Lumina试验中Amx0114在ALS中安全性和耐受性Cohort 1的新数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106700622","title":"Amylyx Pharma 第四季度每股收益$(0.55) 未达到预期$(0.52)","url":"https://stock-news.laohu8.com/highlight/detail?id=1106700622","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106700622?lang=zh_cn&edition=full","pubTime":"2025-03-04 19:14","pubTimestamp":1741086875,"startTime":"0","endTime":"0","summary":"Amylyx Pharma报告季度每股亏损$，低于分析师共识预期的$，低了5.77%。相比去年同期每股收益$0.07，这一结果下降了885.71%。以上内容来自Benzinga Earnings专栏，原文如下：Amylyx Pharma  reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 5.77 percent. This is a 885.71 percent decrease over earnings of $0.07 per share from the same period last year.  The company reported $ in sales this quarter. This is a 100.61 percent decrease over sales of $108.45 million the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Amylyx Pharma 第四季度每股收益$(0.55) 未达到预期$(0.52)","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2488944791","title":"Amylyx Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2488944791","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488944791?lang=zh_cn&edition=full","pubTime":"2024-12-03 23:16","pubTimestamp":1733238980,"startTime":"0","endTime":"0","summary":"北京时间2024年12月03日23时16分，Amylyx Pharmaceuticals, Inc.股票出现异动，股价急速下跌5.02%。Amylyx Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.48%。Amylyx Pharmaceuticals, Inc.公司简介：Amylyx Pharmaceuticals Inc是一家临床阶段的制药公司，致力于开发一种治疗肌萎缩性侧索硬化症和其他神经退行性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203231620a269acce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203231620a269acce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","AMLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2486002790","title":"Amylyx Pharmaceuticals, Inc.盘中异动 早盘急速下跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486002790","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486002790?lang=zh_cn&edition=full","pubTime":"2024-11-26 23:11","pubTimestamp":1732633860,"startTime":"0","endTime":"0","summary":"北京时间2024年11月26日23时11分，Amylyx Pharmaceuticals, Inc.股票出现异动，股价快速跳水5.05%。Amylyx Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.37%。Amylyx Pharmaceuticals, Inc.公司简介：Amylyx Pharmaceuticals Inc是一家临床阶段的制药公司，致力于开发一种治疗肌萎缩性侧索硬化症和其他神经退行性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112623110098e44b1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112623110098e44b1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","AMLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2486308028","title":"Amylyx Pharmaceuticals, Inc.盘中异动 早盘急速上涨5.31%报5.55美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486308028","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486308028?lang=zh_cn&edition=full","pubTime":"2024-11-25 22:33","pubTimestamp":1732545224,"startTime":"0","endTime":"0","summary":"北京时间2024年11月25日22时33分，Amylyx Pharmaceuticals, Inc.股票出现异动，股价急速拉升5.31%。Amylyx Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.06%。其相关个股中，Scholar Rock Holding Corporation、Bridgebio Pharma, Inc.、Citius Pharmaceuticals, Inc.涨幅较大，Cognition Therapeutics, Inc.、木薯科学、Citius Pharmaceuticals, Inc.较为活跃，换手率分别为87.20%、61.57%、38.68%，振幅较大的相关个股有Anixa Biosciences, Inc.、Werewolf Therapeutics, Inc.、Kodiak Sciences Inc，振幅分别为105.47%、105.26%、105.01%。Amylyx Pharmaceuticals, Inc.公司简介：Amylyx Pharmaceuticals Inc是一家临床阶段的制药公司，致力于开发一种治疗肌萎缩性侧索硬化症和其他神经退行性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112522334998e4465d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112522334998e4465d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","AMLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2484326676","title":"Amylyx Pharmaceuticals, Inc.盘中异动 股价大涨15.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484326676","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484326676?lang=zh_cn&edition=full","pubTime":"2024-11-18 22:33","pubTimestamp":1731940389,"startTime":"0","endTime":"0","summary":"北京时间2024年11月18日22时33分，Amylyx Pharmaceuticals, Inc.股票出现波动，股价快速上涨15.13%。Amylyx Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.15%。其相关个股中，Hcw Biologics Inc.、冠科美博、Fate Therapeutics, Inc.涨幅较大，Tharimmune, Inc.、Hcw Biologics Inc.、冠科美博较为活跃，换手率分别为517.53%、210.81%、189.81%，振幅较大的相关个股有Hcw Biologics Inc.、Fate Therapeutics, Inc.、冠科美博，振幅分别为50.92%、35.15%、34.31%。Amylyx Pharmaceuticals, Inc.公司简介：Amylyx Pharmaceuticals Inc是一家临床阶段的制药公司，致力于开发一种治疗肌萎缩性侧索硬化症和其他神经退行性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111822330995be488b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111822330995be488b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AMLX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2483802205","title":"Amylyx Pharmaceuticals, Inc.盘中异动 股价大跌5.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483802205","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483802205?lang=zh_cn&edition=full","pubTime":"2024-11-14 22:30","pubTimestamp":1731594656,"startTime":"0","endTime":"0","summary":"北京时间2024年11月14日22时30分，Amylyx Pharmaceuticals, Inc.股票出现异动，股价大幅跳水5.37%。Amylyx Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Amylyx Pharmaceuticals, Inc.公司简介：Amylyx Pharmaceuticals Inc是一家临床阶段的制药公司，致力于开发一种治疗肌萎缩性侧索硬化症和其他神经退行性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114223056971a68b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114223056971a68b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AMLX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2483598568","title":"Amylyx Pharmaceuticals, Inc.盘中异动 下午盘股价大跌5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483598568","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483598568?lang=zh_cn&edition=full","pubTime":"2024-11-14 03:17","pubTimestamp":1731525429,"startTime":"0","endTime":"0","summary":"北京时间2024年11月14日03时17分，Amylyx Pharmaceuticals, Inc.股票出现波动，股价大幅跳水5.29%。Amylyx Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.32%。其相关个股中，Nkgen Biotech Inc C/Wts 31/05/2028、Pulmatrix, Inc.、Calidi Biotherapeutics, Inc.涨幅较大，Cyclacel Pharmaceuticals, Inc.、Elevai Labs, Inc.、Calidi Biotherapeutics, Inc.较为活跃，换手率分别为549.55%、486.87%、153.44%，振幅较大的相关个股有Psyence Biomedical Ltd C/Wts 25/01/2029、Pulmatrix, Inc.、Celularity Inc C/Wts 16/07/2026 ，振幅分别为132.00%、86.83%、73.71%。Amylyx Pharmaceuticals, Inc.公司简介：Amylyx Pharmaceuticals Inc是一家临床阶段的制药公司，致力于开发一种治疗肌萎缩性侧索硬化症和其他神经退行性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114031709abbe6aa8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114031709abbe6aa8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AMLX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2482684607","title":"Amylyx Pharmaceuticals, Inc.盘中异动 临近收盘股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482684607","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482684607?lang=zh_cn&edition=full","pubTime":"2024-11-12 04:40","pubTimestamp":1731357650,"startTime":"0","endTime":"0","summary":"北京时间2024年11月12日04时40分，Amylyx Pharmaceuticals, Inc.股票出现波动，股价快速上涨5.00%。Amylyx Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.81%。Amylyx Pharmaceuticals, Inc.公司简介：Amylyx Pharmaceuticals Inc是一家临床阶段的制药公司，致力于开发一种治疗肌萎缩性侧索硬化症和其他神经退行性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111204405098e41e10&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111204405098e41e10&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","AMLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2481100850","title":"Amylyx Pharmaceuticals, Inc.盘中异动 股价大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481100850","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481100850?lang=zh_cn&edition=full","pubTime":"2024-11-08 22:45","pubTimestamp":1731077139,"startTime":"0","endTime":"0","summary":"北京时间2024年11月08日22时45分，Amylyx Pharmaceuticals, Inc.股票出现异动，股价大幅上涨5.01%。Amylyx Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.51%。Amylyx Pharmaceuticals, Inc.公司简介：Amylyx Pharmaceuticals Inc是一家临床阶段的制药公司，致力于开发一种治疗肌萎缩性侧索硬化症和其他神经退行性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108224539abae44e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108224539abae44e8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AMLX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.amylyx.com","stockEarnings":[{"period":"1week","weight":0.0208},{"period":"1month","weight":-0.1281},{"period":"3month","weight":-0.0626},{"period":"6month","weight":-0.0507},{"period":"1year","weight":1.9687},{"period":"ytd","weight":0.1772}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0603},{"period":"3month","weight":0.1},{"period":"6month","weight":0.1042},{"period":"1year","weight":0.2839},{"period":"ytd","weight":0.1066}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Amylyx Pharmaceuticals, Inc.于2014年1月10日根据特拉华州法律成立。该公司是一家临床阶段的制药公司，其使命是为医疗需求未得到满足的社区开发和推进新疗法。该公司在神经退行性疾病和内分泌疾病方面正在进行临床前和临床开发项目。该公司正在推进一项管道，在该管道中，该公司已将研究性疗法与认为这些疗法可以产生最大影响的疾病相匹配，基于明确定义的机制原理、明确的临床结果和生物标志物，以及严格的临床前数据，与模式无关。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.074034},{"month":2,"riseRate":0.6,"avgChangeRate":0.089231},{"month":3,"riseRate":0.2,"avgChangeRate":-0.324118},{"month":4,"riseRate":0.4,"avgChangeRate":-0.019949},{"month":5,"riseRate":0.2,"avgChangeRate":-0.0592},{"month":6,"riseRate":0.75,"avgChangeRate":0.347356},{"month":7,"riseRate":1,"avgChangeRate":0.206362},{"month":8,"riseRate":0.5,"avgChangeRate":0.025088},{"month":9,"riseRate":0.75,"avgChangeRate":0.218209},{"month":10,"riseRate":0.75,"avgChangeRate":0.212399},{"month":11,"riseRate":0.75,"avgChangeRate":0.011294},{"month":12,"riseRate":0.25,"avgChangeRate":-0.127185}],"exchange":"NASDAQ","name":"Amylyx Pharmaceuticals","nameEN":"Amylyx Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Amylyx Pharmaceuticals(AMLX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Amylyx Pharmaceuticals(AMLX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Amylyx Pharmaceuticals,AMLX,Amylyx Pharmaceuticals股票,Amylyx Pharmaceuticals股票老虎,Amylyx Pharmaceuticals股票老虎国际,Amylyx Pharmaceuticals行情,Amylyx Pharmaceuticals股票行情,Amylyx Pharmaceuticals股价,Amylyx Pharmaceuticals股市,Amylyx Pharmaceuticals股票价格,Amylyx Pharmaceuticals股票交易,Amylyx Pharmaceuticals股票购买,Amylyx Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Amylyx Pharmaceuticals(AMLX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Amylyx Pharmaceuticals(AMLX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}